



Better Therapeutics Announces Issuance of U.S. Patent Covering Key Features of Their Prescription Digital Therapeutics Platform

June 8, 2022

SAN FRANCISCO--(BUSINESS WIRE)--Jun. 8, 2022-- [Better Therapeutics, Inc.](#) (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that the U.S. Patent and Trade Office (USPTO) has granted their first patent, granting twenty years of exclusivity for a number of key features core to the company's digital therapeutics platform, designed to help treat cardiometabolic diseases through the delivery of digital behavioral therapy as a PDT.

"Our team has been on the cutting edge of using software to help individuals change the behaviors that are the underlying causes of cardiometabolic conditions like type 2 diabetes and fatty liver disease," said Kevin Appelbaum, CEO of Better Therapeutics. "This work has resulted in a number of new and distinct inventions, and we are proud that this ingenuity has now been officially recognized by the USPTO."

The new patent, U.S. Patent No. 11,355,228 granted on June 7th, 2022, is titled "SYSTEM, METHODS, AND APPARATUSES FOR MANAGING DATA FOR ARTIFICIAL INTELLIGENCE SOFTWARE AND MOBILE APPLICATIONS IN DIGITAL HEALTH THERAPEUTICS," and covers methods and apparatus for generating and monitoring a therapy regimen employing Better Therapeutics' innovative machine learning techniques. Taken together with the 510 days of patent term adjustment provided by the U.S. Patent and Trademark Office, Better Therapeutics' exclusivity will extend until at least September of 2039, absent any further patent extensions.

The mechanisms covered in the patent are core to Better Therapeutics' digital platform and relate to the way in which it uses machine learning and artificial intelligence to personalize treatment for each patient in order to optimize adherence and outcomes. Better Therapeutics remains on track to file its *de novo* submission to FDA for its first product - BT-001, a treatment for type 2 diabetes – following the completion of its pivotal clinical trial this month.

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions. The cognitive behavioral therapy delivered by Better Therapeutics' PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

For more information visit: [bettertx.com](https://www.bettertx.com)

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220608005320/en/): <https://www.businesswire.com/news/home/20220608005320/en/>

Investor Relations:

Mark Heinen

IR@bettertx.com

Media:

Peter Duckler at Real Chemistry

pduckler@realchemistry.com

Source: Better Therapeutics, Inc.